Serum levels of matrix metalloproteinase-9 predict lymph node metastasis in breast cancer patients

Oncology Reports

Volumn 31, Issue 4, 2014, Pages 1567-1572

  Heo, Dong Sik ^a   Choi, Hoon ^a   Yeom, Mi Young ^a   Song, Byung Joo ^b   Oh, Se Jeong ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Biological marker; Breast cancer; Matrix metalloproteinase 2; Matrix metalloproteinase 9

Indexed keywords

GELATINASE A; GELATINASE B;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BENIGN TUMOR; BLOOD SAMPLING; BREAST CANCER; BREAST TUMOR; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FOLDING; ZYMOGRAPHY;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LYMPHATIC METASTASIS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 84908147310     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3001     Document Type: Article

References (24)

1. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B and Senn HJ: Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16: 1569-1583, 2005.
2. Thomssen C and Janicke F: Do we need better prognostic factors in node-negative breast cancer? Eur J Cancer 36: 293-298, 2000.
3. Talvensaari-Mattila A, Paakko P, Hoyhtya M, Blanco-Sequeiros G and Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer 83: 1153-1162, 1998.
4. Li HC, Cao DC, Liu Y, et al: Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat 88: 75-85, 2004.
5. Giambernardi TA, Grant GM, Taylor GP, et al: Overview of matrix metalloproteinase expression in cultured human cells. Matrix Biol 16: 483-496, 1998.
6. Iwasaki M, Nishikawa A, Fujimoto T, et al: Anti-invasive effect of MMI-166, a new selective matrix metalloproteinase inhibitor, in cervical carcinoma cell lines. Gynecol Oncol 85: 103-107, 2002.
7. Kato Y, Yamashita T and Ishikawa M: Relationship between expression of matrix metalloproteinase-2 and matrix metalloproteinase-9 and invasion ability of cervical cancer cells. Oncol Rep 9: 565-569, 2002.
8. McMasters KM, Giuliano AE, Ross MI, et al: Sentinel-lymph-node biopsy for breast cancer - not yet the standard of care. N Engl J Med 339: 990-995, 1998.
9. Curran S, Dundas SR, Buxton J, Leeman MF, Ramsay R and Murray GI: Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res 10: 8229-8234, 2004.
10. Forget MA, Desrosiers RR and Beliveau R: Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis. Can J Physiol Pharmacol 77: 465-480, 1999.
11. Duffy MJ, Maguire TM, Hill A, McDermott E and O'Higgins N: Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2: 252-257, 2000.
12. Giannelli G, Bergamini C, Fransvea E, Marinosci F, Quaranta V and Antonaci S: Human hepatocellular carcinoma (HCC) cells require both alpha3beta1 integrin and matrix metalloproteinases activity for migration and invasion. Lab Invest 81: 613-627, 2001.
13. Vasala K, Paakko P and Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer. Urology 62: 952-957, 2003.
14. Gerhards S, Jung K, Koenig F, et al: Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. Urology 57: 675-679, 2001.
15. Liabakk NB, Talbot I, Smith RA, Wilkinson K and Balkwill F: Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 56: 190-196, 1996.
16. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM and Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67-68, 1980.
17. Davies B, Miles DW, Happerfield LC, et al: Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 67: 1126-1131, 1993.
18. Brown PD, Bloxidge RE, Anderson E and Howell A: Expression of activated gelatinase in human invasive breast carcinoma. Clin Exp Metastasis 11: 183-189, 1993.
19. Di Carlo A, Terracciano D, Mariano A and Macchia V: Matrix metalloproteinase-2 and matrix metalloproteinase-9 type IV collagenases in serum of patients with pleural effusions. Int J Oncol 26: 1363-1368, 2005.
20. Daniele A, Zito AF, Giannelli G, et al: Expression of metalloproteinases MMP-2 and MMP-9 in sentinel lymph node and serum of patients with metastatic and non-metastatic breast cancer. Anticancer Res 30: 3521-3527, 2010.
21. Hanemaaijer R, Verheijen JH, Maguire TM, et al: Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors. Int J Cancer 86: 204-207, 2000.
22. Zucker S, Hymowitz M, Conner C, et al: Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann NY Acad Sci 878: 212-227, 1999.
23. Kjeldsen L, Bjerrum OW, Hovgaard D, Johnsen AH, Sehested M and Borregaard N: Human neutrophil gelatinase: a marker for circulating blood neutrophils. Purification and quantitation by enzyme linked immunosorbent assay. Eur J Haematol 49: 180-191, 1992.
24. Ranuncolo SM, Armanasco E, Cresta C, Bal De Kier Joffe E and Puricelli L: Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int J Cancer 106: 745-751, 2003.